Arch Therapeutics, Inc. (ARTH)
- Previous Close
1.1800 - Open
1.1800 - Bid --
- Ask --
- Day's Range
1.1400 - 1.1800 - 52 Week Range
0.3900 - 18.0000 - Volume
313 - Avg. Volume
4,229 - Market Cap (intraday)
5.406M - Beta (5Y Monthly) 3.56
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4000 - Earnings Date May 20, 2024 - May 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.
www.archtherapeutics.comRecent News: ARTH
Performance Overview: ARTH
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARTH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARTH
Valuation Measures
Market Cap
5.60M
Enterprise Value
12.53M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
40.30
Price/Book (mrq)
--
Enterprise Value/Revenue
108.68
Enterprise Value/EBITDA
-3.05
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-185.96%
Return on Equity (ttm)
--
Revenue (ttm)
115.33k
Net Income Avi to Common (ttm)
-7.86M
Diluted EPS (ttm)
-1.4000
Balance Sheet and Cash Flow
Total Cash (mrq)
205.85k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.96M
Research Analysis: ARTH
Company Insights: ARTH
ARTH does not have Company Insights